Evidence map›Paper›PMID 37408496›Full record

ArticleMolecular oncology2023

Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1.

Iva Trsova, Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Aleš Holoubek, Karolina Staflova, Lucie Janstova, Sarka Vanikova, Katarina Szikszai, Jiri Klema and 10 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Circular RNA in cancer.Nature reviews. Cancer · 2024
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Iva TrsovaDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Andrea HrustincovaDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Zdenek KrejcikDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
David KundratDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Aleš HoloubekDepartment of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Karolina StaflovaDepartment of Biochemistry, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Lucie JanstovaDepartment of Modern Immunotherapy, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Sarka VanikovaDepartment of Immunomonitoring and Flow Cytometry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Katarina SzikszaiDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Jiri KlemaDepartment of Computer Science, Czech Technical University, Prague, Czech Republic.
Petr RysavyDepartment of Computer Science, Czech Technical University, Prague, Czech Republic.
Monika BelickovaDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Monika KaisrlikovaDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Jitka VeselaDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Jaroslav CermakLaboratory of Anemias, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Anna JonasovaFirst Department of Medicine, General University Hospital, Prague, Czech Republic.
Jiri DostalDepartment of Biochemistry, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.
Jan FricDepartment of Modern Immunotherapy, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Jan MusilDepartment of Immunomonitoring and Flow Cytometry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Michaela Dostalova MerkerovaDepartment of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.ORCID 0000-0002-6345-9180
Institute of Haematology and Blood Transfusion · CZCharles University · CZCzech Technical University in Prague · CZInstitute of Organic Chemistry · PLGeneral University Hospital in Prague · CZ

Funding

Grantová Agentura České Republiky 20-19162SMinisterstvo Zdravotnictví Ceské Republiky 00023736Ústav organické chemie a biochemie Akademie věd České republiky RVO 61388963
6 · The paper itself

Abstract

Mutations in the splicing factor 3b subunit 1 (SF3B1) gene are frequent in myelodysplastic neoplasms (MDS). Because the splicing process is involved in the production of circular RNAs (circRNAs), we investigated the impact of SF3B1 mutations on circRNA processing. Using RNA sequencing, we measured circRNA expression in CD34+ bone marrow MDS cells. We defined circRNAs deregulated in a heterogeneous group of MDS patients and described increased circRNA formation in higher-risk MDS. We showed that the presence of SF3B1 mutations did not affect the global production of circRNAs; however, deregulation of specific circRNAs was observed. Particularly, we demonstrated that strong upregulation of circRNAs processed from the zinc finger E-box binding homeobox 1 (ZEB1) transcription factor; this upregulation was exclusive to SF3B1-mutated patients and was not observed in those with mutations in other splicing factors or other recurrently mutated genes, or with other clinical variables. Furthermore, we focused on the most upregulated ZEB1-circRNA, hsa_circ_0000228, and, by its knockdown, we demonstrated that its expression is related to mitochondrial activity. Using microRNA analyses, we proposed miR-1248 as a direct target of hsa_circ_0000228. To conclude, we demonstrated that mutated SF3B1 leads to deregulation of ZEB1-circRNAs, potentially contributing to the defects in mitochondrial metabolism observed in SF3B1-mutated MDS.

Indexed as

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesHumansMutationPhosphoproteinsRNA, CircularRNA Splicing FactorsTranscription FactorsPhosphoproteinsRNA, CircularRNA Splicing FactorsSF3B1 protein, humanTranscription Factorscircular RNAmyelodysplastic neoplasmsSF3B1splicingZEB1

Identifiers

PMID37408496
PMCPMC10701770
OpenAlexW4383302735

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.